The global microfluidic devices market was valued at $20,971.0 million in 2021, and is projected to reach $158,119.5 million by 2031, registering a CAGR of 22.4% from 2022 to 2031.
Microfluidics is the study of systems that can process small quantities of fluids by using tiny channels having dimensions at the microscale - typically tens to hundreds of micrometers. Microfluidics allows the analysis and use of less volume of samples, chemicals and reagents reducing the global fees of applications.
The increase in prevalence of various infectious diseases such as Flu A, B and diphtheria boosts the growth of the market. Microfluidics are used in the diagnostics of various infectious diseases. In addition, novel approach for the cost-effective diagnosis of tuberculosis further contributes toward the growth of the market. For instance, according to world health organization (WHO), a total of 1.5 million people died from tuberculosis in 2020 worldwide, and tuberculosis is the thirteenth leading cause of death. Thus, increase in prevalence of infectious diseases and rise in use of microfluidics for diagnosis drive the growth of the market.
Moreover, microfluidics are highly sensitive and cost effective which drives the demand for microfluidics devices in diagnosis. In addition, the microfluidics device-based diagnosis requires less quantity of sample and easy product type of operation which boosts the adoption of microfluidics in diagnosis
Furthermore, increase in prevalence of autoimmune disease such as rheumatoid arthritis, scleroderma, and lupus contributes toward the growth of the market. For instance, according to global RA network, approximately 350 million people have arthritis globally. Arthritis, or joint disease, is inflammation of one or more of the joints, such as the knees, knuckles, wrists, or ankles. Arthritis starts as joint inflammation but can progress into joint pain, swelling, and stiffness. A microfluidic chip was recently developed to detect autoimmune diseases. The device measures the number of specified antibodies in the blood.
Moreover, increase in R&D activities for development of advanced microfluidics device such as 3D printing & robotics, rise in U.S. food and drug administration (USFDA) approvals and novel product launch in the market by key players boost the market growth. For instance, in December 2020, Conformis, Inc., a leader in patient-specific knee and hip instrumentation and implants, announced today the U.S. commercial launch of the Company’s new Cordera Match Hip System. Furthermore, advancements in microfluidics devices such as robotics and navigation support further contribute toward the market growth. However, high cost of microfluidics devices and product recall are anticipated to hinder the growth of the market.
The microfluidics device market is segmented on the basis of product type, application, end user and region. By product type, the market is divided into microfluidic-based devices and microfluidic components. The microfluidic components segment is classified into microfluidic chips, flow & pressure sensors, flow & pressure controllers, microfluidic valves, micropumps, microneedles and other components.
Depending on application, the market is classified into in-vitro diagnostics, pharmaceutical & life science research & manufacturing and therapeutics. The in-vitro diagnostics segment is further classified into clinical diagnostics, point-of-care testing and veterinary diagnostics. The pharmaceutical & life science research & manufacturing and therapeutics segment is further classified into lab analytics, microdispensing and microreaction. The lab analytics segment is further categorized into proteomics, genomics, cell-based assays and capillary electrophoresis.
The therapeutics segment is further classified into drug delivery and wearable devices.
Based on end user, the market is categorized into hospitals & diagnostic centers, academic & research institutes, and pharmaceutical & biotechnology companies. By region segment, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include Lonza Group, Thermo Fisher Scientific Inc., Perkinelmer Inc., Biorad Laboratories, Inc., Illumina, Inc., Qiagen N.V., Fluidigm Corporation, Dolomite Microfluidics, bioMérieux SA, Abbott Laboratories, Danaher Corporation, SMC Corporation, Idex Corporation, Fortive Corporation, Agilent Technologies, Inc., Nanostring and Nortis Inc.
Microfluidics is the study of systems that can process small quantities of fluids by using tiny channels having dimensions at the microscale - typically tens to hundreds of micrometers. Microfluidics allows the analysis and use of less volume of samples, chemicals and reagents reducing the global fees of applications.
The increase in prevalence of various infectious diseases such as Flu A, B and diphtheria boosts the growth of the market. Microfluidics are used in the diagnostics of various infectious diseases. In addition, novel approach for the cost-effective diagnosis of tuberculosis further contributes toward the growth of the market. For instance, according to world health organization (WHO), a total of 1.5 million people died from tuberculosis in 2020 worldwide, and tuberculosis is the thirteenth leading cause of death. Thus, increase in prevalence of infectious diseases and rise in use of microfluidics for diagnosis drive the growth of the market.
Moreover, microfluidics are highly sensitive and cost effective which drives the demand for microfluidics devices in diagnosis. In addition, the microfluidics device-based diagnosis requires less quantity of sample and easy product type of operation which boosts the adoption of microfluidics in diagnosis
Furthermore, increase in prevalence of autoimmune disease such as rheumatoid arthritis, scleroderma, and lupus contributes toward the growth of the market. For instance, according to global RA network, approximately 350 million people have arthritis globally. Arthritis, or joint disease, is inflammation of one or more of the joints, such as the knees, knuckles, wrists, or ankles. Arthritis starts as joint inflammation but can progress into joint pain, swelling, and stiffness. A microfluidic chip was recently developed to detect autoimmune diseases. The device measures the number of specified antibodies in the blood.
Moreover, increase in R&D activities for development of advanced microfluidics device such as 3D printing & robotics, rise in U.S. food and drug administration (USFDA) approvals and novel product launch in the market by key players boost the market growth. For instance, in December 2020, Conformis, Inc., a leader in patient-specific knee and hip instrumentation and implants, announced today the U.S. commercial launch of the Company’s new Cordera Match Hip System. Furthermore, advancements in microfluidics devices such as robotics and navigation support further contribute toward the market growth. However, high cost of microfluidics devices and product recall are anticipated to hinder the growth of the market.
The microfluidics device market is segmented on the basis of product type, application, end user and region. By product type, the market is divided into microfluidic-based devices and microfluidic components. The microfluidic components segment is classified into microfluidic chips, flow & pressure sensors, flow & pressure controllers, microfluidic valves, micropumps, microneedles and other components.
Depending on application, the market is classified into in-vitro diagnostics, pharmaceutical & life science research & manufacturing and therapeutics. The in-vitro diagnostics segment is further classified into clinical diagnostics, point-of-care testing and veterinary diagnostics. The pharmaceutical & life science research & manufacturing and therapeutics segment is further classified into lab analytics, microdispensing and microreaction. The lab analytics segment is further categorized into proteomics, genomics, cell-based assays and capillary electrophoresis.
The therapeutics segment is further classified into drug delivery and wearable devices.
Based on end user, the market is categorized into hospitals & diagnostic centers, academic & research institutes, and pharmaceutical & biotechnology companies. By region segment, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include Lonza Group, Thermo Fisher Scientific Inc., Perkinelmer Inc., Biorad Laboratories, Inc., Illumina, Inc., Qiagen N.V., Fluidigm Corporation, Dolomite Microfluidics, bioMérieux SA, Abbott Laboratories, Danaher Corporation, SMC Corporation, Idex Corporation, Fortive Corporation, Agilent Technologies, Inc., Nanostring and Nortis Inc.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the microfluidic devices market analysis from 2021 to 2031 to identify the prevailing microfluidic devices market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the microfluidic devices market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global microfluidic devices market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product
- Microfluidic-based Devices
- Microfluidic Components
- Type
- Microfluidic Chips
- Flow Pressure Sensors
- Flow Pressure Controllers
- Microfluidic Valves
- Micropumps
- Microneedles
- Other Components
By Application
- In-vitro Diagnostics
- Type
- Clinical Diagnostics
- Point-of-care Testing
- Veterinary Diagnostics
- Pharmaceutical Life Science Research and Manufacturing
- Type
- Lab Analytics
- Microdispensing
- Microreaction
- Therapeutics
- Type
- Drug Delivery
- Wearable Devices
By End User
- Hospitals Diagnostic Centers
- Academic Research Institutes
- Pharmaceutical Biotechnology Companies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Soudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Lonza Group
- Thermo Fisher Scientific Inc.
- Perkinelmer Inc.
- Biorad Laboratories, Inc.
- Illumina, Inc.
- Qiagen N.V.
- Fluidigm Corporation
- Dolomite Microfluidics
- bioMérieux SA
- Abbott Laboratories
- Danaher Corporation
- SMC Corporation
- Idex Corporation
- Fortive Corporation
- Agilent Technologies, Inc.
- Nanostring
- Nortis Inc.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: MICROFLUIDIC DEVICES MARKET, BY PRODUCT
CHAPTER 5: MICROFLUIDIC DEVICES MARKET, BY APPLICATION
CHAPTER 6: MICROFLUIDIC DEVICES MARKET, BY END USER
CHAPTER 7: MICROFLUIDIC DEVICES MARKET, BY REGION
CHAPTER 8: COMPANY LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report, titled, “Microfluidic Devices Market," the microfluidic devices market was valued at $21 billion in 2021, and is estimated to reach $158.1 billion by 2031, growing at a CAGR of 22.4% from 2021 to 2031.Microfluidic devices exploit the physical and chemical properties of liquids and gases at a microscale. Microfluidic devices offer several benefits over conventionally sized systems. Microfluidics allow the analysis and use of less volume of samples, chemicals and reagents reducing the global fees of applications.
The increase in prevalence of infectious diseases and cancer drives the growth of the Microfluidic Devices Market. Microfluidics devices are used for the diagnosis of infectious diseases. For instance, according to World Health Organization (WHO), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. The microfluidics platforms are being used to detect genetic mutations that correspond to breast cancer, including DNA and miRNA mutations. Microfluidics platforms are able to analyze more sample volume in a shorter amount of time than traditional detection methods owing to their high throughput and low time requirements.
Furthermore, rise in number of geriatric populations boosts the growth of the Microfluidic Devices Market size. Old age people are more prone to infectious diseases and cancer. Thus, geriatric population signifies increase in patients of chronic diseases. For instance, according to World Health Organization (WHO), by 2050, the world’s population of people aged 60 years and older will reached to 2.1 billion.
Advancement in technology by key players for the development and manufacturing of microfluidic device contributes to drive the growth of the Microfluidic Industry. Increase in the awareness regarding use of micro pump in medical device and effectiveness of microfluidic components in drug delivery system cause rise in the demand of microfluidic system in biomedical industry. Thus, this factor is anticipated to drive the market growth. Moreover, increase in number of pharmaceutical and biotechnology companies cause rise in the demand for micro pump which boosts the market growth
Furthermore, Microfluidic Devices Market trends that drive the Microfluidic Devices Market growth include R&D for development of microfluidics device, increase in product type approvals, and new product launched in market. For instance, in November 2021, Fluidigm Corporation, a biotechnology tools provider with a vision to improve life through comprehensive health insight, has announced the launch of Biomark X, the latest generation of its Biomark microfluidics platform. Biomark X integrates the Fluidigm Juno and Biomark HD instruments into a single platform while adding an expansive set of sample-to-answer capabilities on a single versatile, scalable and transformative genomics platform. Furthermore, the rise in healthcare expenditure and improvements in healthcare facilities in developing nations contributes towards growth of the microfluidics device market.
The microfluidics device market is segmented into by product type, application, end user, and region.
On the basis of product type, the market is divided into microfluidic-based devices and microfluidic components. The microfluidic components segment dominated the market in 2021, and this trend is expected to continue during the forecast period, owing to growing demand for microfluidics devices and rise in adoption of microfluidics in diagnosis & drug delivery.
On the basis of application, the market is categorized into in-vitro diagnostics, pharmaceutical & life science research & manufacturing and therapeutics. The in-vitro diagnostics segment dominated the Microfluidic Devices Market share in 2021, and this trend is expected to continue during the forecast period, owing to increase in prevalence of infectious diseases and autoimmune diseases.
On the basis of end user, the market is classified into hospitals & diagnostic centers, academic & research institutes and pharmaceutical & biotechnology companies. The hospitals & diagnostic centers segment dominated the market in 2021, and this trend is expected to continue during the forecast period, owing to growing application in diagnosis of infectious diseases and rise in healthcare expenditures.
North America accounted for a majority of the global microfluidics device market share in 2021, and is anticipated to remain dominant during the forecast period. This is attributed to rise in prevalence of infectious diseases, well established healthcare infrastructure and presence of key players in the region. Asia-Pacific is anticipated to witness lucrative growth, owing to increase in incidences of cancer, growing geriatric population and high population base.
Key Findings of the Study
- On the basis of product type, the microfluidic components segment was the highest contributor to the market in 2021.
- On the basis of application, the in-vitro diagnostics segment was the highest contributor to the market in 2021.
- On the basis of end user, the hospitals & diagnostic centers segment was the highest contributor to the market in 2021.
- On the basis of region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period
Companies Mentioned
- Lonza Group
- Thermo Fisher Scientific Inc.
- Perkinelmer Inc.
- Biorad Laboratories, Inc.
- Illumina, Inc.
- Qiagen N.V.
- Fluidigm Corporation
- Dolomite Microfluidics
- Biomérieux Sa
- Abbott Laboratories
- Danaher Corporation
- Smc Corporation
- Idex Corporation
- Fortive Corporation
- Agilent Technologies, Inc.
- Nanostring
- Nortis Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 220 |
| Published | July 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 20971 million |
| Forecasted Market Value ( USD | $ 158119.5 million |
| Compound Annual Growth Rate | 22.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 17 |
